Verkkogrifols is accelerating adoption of xembify® as part of its broader immunoglobulin business strategy focused on treating immunodeficiency disorders,. Verkkorare diseases remain a formidable public health challenge. The key to unlocking breakthroughs in diagnosis and treatment is fostering dynamic. $7. 5m allocated to.